• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Global Lung Cancer Therapeutics Market 2015-2019 - Product Image

Global Lung Cancer Therapeutics Market 2015-2019

  • ID: 2408115
  • November 2014
  • Region: Global
  • 126 pages
  • TechNavio

FEATURED COMPANIES

  • Abbvie
  • AstraZeneca
  • Eisai
  • GTx
  • Novartis
  • Pfizer
  • MORE

About Lung Cancer

Cancer occurs when, after undergoing cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Non-small cell lung cancer is the commonest type of lung cancer and forms almost 85-90 percent of the total cases diagnosed. It grows and spreads slowly. Smoking is considered as a major cause of lung cancer, though lung cancer also occurs in non-smokers. Non-small cell lung cancer is of three types: squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. Small cell lung cancers form roughly 10-15 percent of all the diagnosed cases of lung cancer. There are two types of small cell lung cancer: small cell carcinoma and combined small cell carcinoma. It can be classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer cannot be cured using current therapies available in the market. Some of the common symptoms associated with lung cancer are chest pain, persistent cough, blood in sputum, fatigue, loss of appetite, weight loss, shortness of breath, READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie
  • AstraZeneca
  • Eisai
  • GTx
  • Novartis
  • Pfizer
  • MORE

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Iressa
04.1.2 Abraxane
04.1.3 Alimta
04.1.4 Gemzar
04.1.5 Xalkori
04.1.6 Avastin
04.1.7 Tarceva
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1 Understanding the Disease
07.2 Economic Burden
07.3 Classification of Lung Cancer
07.4 Diagnosis
07.5 Small Cell Lung Cancer
07.5.1 Rate of Incidence and Prevalence
07.5.2 Staging
07.5.3 Management
07.6 Non-small Cell Lung Cancer
07.6.1 Rate of Incidence and Prevalence
07.6.2 Staging
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Disease Type
09.1 Global Non-small Cell Lung Cancer Therapeutics Market
09.1.1 Market Size and Forecast
09.1.2 Market Segmentation by Molecule Type
09.1.3 Market Segmentation by Routes of Administration
09.2 Global Small Cell Lung Cancer Therapeutics Market
09.2.1 Market Size and Forecast
10. Market Segmentation by Molecule Type
10.1 Biologics
10.2 Small Molecules
11. Market Segmentation by Route of Administration
11.1 Oral
11.2 Parenteral
12. Geographical Segmentation
12.1 Global Non-Small-Cell Lung Cancer Market
12.2 Global Small Cell Lung Cancer Market
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 AstraZeneca
20.2.2 Celgene
20.2.3 Eli Lilly
20.2.4 F. Hoffmann-La Roche
20.2.5 Pfizer
20.3 Other and Future Prominent Vendors
21. Pipeline Portfolio
21.1.1 Non-small Cell Lung Cancer
21.1.2 Small Cell Lung Cancer
22. Key Vendor Analysis
22.1 AstraZeneca
22.1.1 Key Facts
22.1.2 Business Description
22.1.3 Business Segmentation
22.1.4 Business Strategy
22.1.5 Revenue by Business Segmentation
22.1.6 Revenue Comparison 2011-2013
22.1.7 Sales Revenue by Geographical Segmentation
22.1.8 Key Developments
22.1.9 SWOT Analysis
22.2 Celgene
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Strategy
22.2.4 Business Segmentation by Revenue
22.2.5 Sales by Geography
22.2.6 Key Information
22.2.7 SWOT Analysis
22.3 Eli Lilly
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation by Revenue
22.3.4 Sales by Geography
22.3.5 Business Strategy
22.3.6 Key Information
22.3.7 SWOT Analysis
22.4 F. Hoffmann-La Roche Ltd.
22.4.1 Key Facts
22.4.2 Business Overview
22.4.3 Business Segmentation
22.4.4 Business Segmentation by Revenue 2012 and 2013
22.4.5 Sales by Geography
22.4.6 Business Strategy
22.4.7 Key Information
22.4.8 SWOT Analysis
22.5 Pfizer
22.5.1 Key Facts
22.5.2 Business Overview
22.5.3 Business Segmentation by Revenue 2013
22.5.4 Business Segmentation by Revenue 2012 and 2013
22.5.5 Geographical Segmentation by Revenue
22.5.6 Business Strategy
22.5.7 Key Developments
22.5.8 SWOT Analysis
23. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Incidence Data of Lung Cancer pertaining to WHO Regions
Exhibit 3: Classification of Lung Cancer Types
Exhibit 4: Diagnosis of Lung Cancer in Patients
Exhibit 5: Staging of Small Cell Lung Cancer
Exhibit 6: Stepwise Diagrammatic Representation of the Management of Small Cell Lung Cancer According to the ESMO Guidelines
Exhibit 7: Types of Non-small Cell Lung Cancer
Exhibit 8: Percentage of Gene Mutations in Non-small Cell Lung Cancer
Exhibit 9: Staging of Non-small Cell Lung Cancer
Exhibit 10: Global Lung Cancer Therapeutics Market 2014-2019 (US$ million)
Exhibit 11: Global Lung Cancer Therapeutics Market Segmentation by Disease Type
Exhibit 12: Global Lung Cancer Therapeutics Market Segmentation by Disease Type 2014
Exhibit 13: YoY Revenue Comparison of Global Non-small Cell Lung Cancer Therapeutics market and Global Small Cell Lung Cancer Therapeutics market 2014-2019 (US$ million)
Exhibit 14: Global Non-small Cell Lung Cancer Therapeutics Market 2014-2019 (US$ million)
Exhibit 15: Global Non-Small-Cell Lung Cancer Market Segmentation by Molecule Type
Exhibit 16: Global Non-Small-Cell Lung Cancer Market Segmentation by Molecule Type 2014
Exhibit 17: Global Non-Small-Cell Lung Cancer Market Segmentation by Route of Administration
Exhibit 18: Global Non-Small-Cell Lung Cancer Market Segmentation by Routes of Administration 2014
Exhibit 19: Global Small Cell Lung Cancer Therapeutics Market 2014-2019 (US$ million)
Exhibit 20: Global Lung Cancer Therapeutics Market Segmentation by Molecule Type
Exhibit 21: Global Lung Cancer Therapeutics Market Segmentation by Molecule Type 2014
Exhibit 22: Global Lung Cancer Therapeutics Market Segmentation by Route of Administration
Exhibit 23: Global Lung Cancer Therapeutics Market Segmentation by Route of Administration 2014
Exhibit 24: Global Lung Cancer Therapeutics Market by Geographical Segmentation 2014
Exhibit 25: Global Non-small Cell Lung Cancer Market by Geographical Segmentation 2014
Exhibit 26: Global Small Cell Lung Cancer Market by Geographical Segmentation 2014
Exhibit 27: Buying Criteria of Global Lung Cancer Therapeutics Market 2014
Exhibit 28: Drivers of the Global Lung Cancer Therapeutics Market
Exhibit 29: Challenges of the Global Lung Cancer Therapeutics Market
Exhibit 30: Trends of the Global Lung Cancer Therapeutics Market
Exhibit 31: Global Lung Cancer Therapeutics Market by Vendor Segmentation 2014
Exhibit 32: Global Non-Small-Cell Lung Cancer Market by Market Share Analysis 2014
Exhibit 33: Sales Comparison of Major Drugs 2010-2013 (US$ million)
Exhibit 34: Sales of Iressa 2006-2013 (US$ million)
Exhibit 35: Sales of Iressa in Western Europe 2009-2013 (US$ million)
Exhibit 36: Sales of Iressa in Established ROW 2009-2013 (US$ million)
Exhibit 37: Sales of Iressa in Emerging Markets 2009-2013 (US$ million)
Exhibit 38: Region-wise Sales of Iressa 2009-2011 (US$ million)
Exhibit 39: Sales of Abraxane 2010-2013 (US$ million)
Exhibit 40: Sales of Alimta in US 2004-2013 (US$ million)
Exhibit 41: Sales of Alimta Outside US 2004-2013 (US$ million)
Exhibit 42: Total Sales of Alimta 2004-2013 (US$ million)
Exhibit 43: Region-wise Sales of Alimta 2004-2013 (US$ million)
Exhibit 44: Sales of Gemzar in US 2003-2011 (US$ million)
Exhibit 45: Sales of Gemzar Outside US 2003-2011 (US$ million)
Exhibit 46: Total Sales of Gemzar 2003-2011 (US$ million)
Exhibit 47: Region-wise Sales Gemzar 2003-2011 (US$ million)
Exhibit 48: Sales of Avastin and Tarceva 2005-2013 (US$ million)
Exhibit 49: Sales of Avastin 2005-2013 (US$ million)
Exhibit 50: Sales of Tarceva 2005-2013 (US$ million)
Exhibit 51: Sales Forecast for Xalkori 2013-2018 (US$ million)
Exhibit 52: Phase III Pipeline Portfolio of Global Lung Cancer Therapeutics Market by Disease Type 2014
Exhibit 53: Late-stage Pipeline Molecules for Non-small Cell Lung Cancer
Exhibit 54: Late-stage Pipeline Molecules for Small Cell Lung Cancer
Exhibit 55: Study Count of Small Cell Lung Cancer Clinical Trials by Geography
Exhibit 56: Study Count of Non-small Cell Lung Cancer Clinical Trials by Geography
Exhibit 57: AstraZeneca: Business Segmentation
Exhibit 58: AstraZeneca: Revenue by Business Segmentation 2013
Exhibit 59: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 60: AstraZeneca: Sales Revenue by Geographical Segmentation 2013
Exhibit 61: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 62: Celgene: Sales by Geography 2013
Exhibit 63: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 64: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 65: Eli Lilly: Sales by Geography 2013
Exhibit 66: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 67: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 68: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 69: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 70: Pfizer: Business Segmentation by Revenue 2013
Exhibit 71: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 72: Pfizer: Geographical Segmentation by Revenue 2013

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie
  • AstraZeneca
  • Eisai
  • GTx
  • Novartis
  • Pfizer
  • MORE

Commenting on the report, an analyst from the team said: “The use of personalized medicine is a major trend in this market. It is based on the genetic structure of the patients, and has fewer adverse side effects compared to chemotherapy, which tends to destroy other healthy cells of the body while killing the malignant cancerous cells.”

According to the report, the high unmet need for appropriate drugs is one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely; hence, the mortality rate of lung cancer patients is high. Therefore, drugs that cause disease remission in patients are expected to significantly drive the growth of the market.

Further, the report states that the high cost of treatment is a major factor that restricts the growth of the market. The drugs that are used for the treatment of cancer are expensive and, hence, get poor response from patients. The patients also tend to withdraw themselves from expensive treatment regimens.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Note: Product cover images may vary from those shown

- AstraZeneca
- Celgene
- Eli Lilly
- F. Hoffmann-La Roche
- Pfizer
- Abbvie
- Aetna
- Agennix
- Amgen
- Boehringer Ingelheim
- Celldex
- Eisai
- GlaxoSmithKline
- GTx
- Helsinn
- IMClone
- Merck Serono
- Novartis
- Qiagen
- OncoGenex
- OSI Pharmaceuticals
- Peregrine
- Pierre Fabre
- Sanofi
- Synta
- Telik
- Teva Pharmaceutical

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos